La Jolla Pharmaceutical Co. (LJPC) - NASDAQ
  • Fri, May 6, 9:20 AM
    • La Jolla Pharmaceutical (LJPC) Q1 results: Revenues: $0.2M; R&D Expense: $12.7M (+144.2%); SG&A: $4.1M (+7.9%); Net Loss: ($16.5M) (-83.3%); Loss Per Share: ($0.96) (-62.7%); Quick Assets: $113.1M (-10.6%).
    • No guidance given.
    | Fri, May 6, 9:20 AM
  • Fri, May 6, 9:07 AM
    • La Jolla Pharmaceutical (NASDAQ:LJPC): Q1 EPS of -$0.96 misses by $0.22.
    • Revenue of $0.23M beats by $0.02M.
    • Press Release
    | Fri, May 6, 9:07 AM
  • Thu, Feb. 25, 5:14 PM
    • La Jolla Pharmaceutical (NASDAQ:LJPC): Q4 EPS of -$0.69 beats by $0.03.
    • Revenue of $0.41M
    • Press Release
    | Thu, Feb. 25, 5:14 PM
  • Nov. 6, 2015, 10:26 AM
    • La Jolla Pharmaceutical (LJPC -4.5%) Q3 results: Revenues: $0.6M; R&D Expense: $7.8M (+200.0%); SG&A: $3.4M (+41.7%); Net Loss: ($10.4M) (-103.9%); Loss Per Share: ($0.70) (-89.2%); Quick Assets: $135.1M (+178.0%).
    • No guidance given.
    | Nov. 6, 2015, 10:26 AM
  • Nov. 6, 2015, 8:32 AM
    • La Jolla Pharmaceutical (NASDAQ:LJPC): Q3 EPS of -$0.70 beats by $0.01.
    • Revenue of $0.65M
    | Nov. 6, 2015, 8:32 AM
  • Sep. 11, 2015, 9:08 AM
    • The European Medicines Agency's Committee for Orphan Medicinal Products (COMP) adopts a positive opinion recommending La Jolla Pharmaceutical's (NASDAQ:LJPC) LJPC-401 an orphan drug for the treatment of chronic iron overload requiring chelation therapy. Chelating agents bind to and help clear excessive iron from the body, but they are toxic. La Jolla's LJPC-401 is a novel formulation of hepcidin, a naturally occurring peptide hormone that prevents the accumulation of iron in organs.
    • Abnormal iron accumulation occurs in disorders such as sickle cell disease, beta thalassemia and hereditary hemochromatosis.
    • Orphan drug status in the EU provides for a 10-year period of market exclusivity for the indication, if approved.
    | Sep. 11, 2015, 9:08 AM
  • Sep. 10, 2015, 9:11 AM
    | Sep. 10, 2015, 9:11 AM | 1 Comment
  • Sep. 9, 2015, 4:37 PM
    • La Jolla Pharmaceutical (NASDAQ:LJPC) commences a public offering of common stock. Price, volume and terms have yet to be announced.
    | Sep. 9, 2015, 4:37 PM | 2 Comments
  • Sep. 8, 2015, 3:58 PM
    • Thinly traded La Jolla Pharmaceutical (LJPC +26.2%) is poised to finish the day up nicely on almost a 4x surge in volume. The market's positive action is certainly the biggest factor. Adding a bit of fuel to the up move was Chardan Capital's price target raise to $80 (83% upside) from $60.
    | Sep. 8, 2015, 3:58 PM | 11 Comments
  • Sep. 8, 2015, 12:41 PM
    | Sep. 8, 2015, 12:41 PM | 1 Comment
  • Aug. 21, 2015, 1:12 PM
    | Aug. 21, 2015, 1:12 PM | 8 Comments
  • Aug. 21, 2015, 12:45 PM
    | Aug. 21, 2015, 12:45 PM
  • Aug. 18, 2015, 8:57 AM
    • The FDA designates two novel compounds from La Jolla Pharmaceutical (NASDAQ:LJPC) Orphan Drugs for the treatment of fibrodysplasia ossificans progressiva (FOP), an extremely rare genetic disorder in which the body's repair mechanism causes fibrous tissue (muscle, tendon, ligament) to be ossified spontaneously or when damaged. The disorder is sometimes called "stone man syndrome" because sufferers are slowly imprisoned by their own skeletons. There are no effective treatments for the condition.
    • The compounds, licensed from Vanderbilt University, are small molecule kinase inhibitors designed to selectively block a specific member of the bone morphogenetic protein ((BMP)) type-1 receptor family called ALK2. The improper activation of these receptor pathways (ALK 1-7) is responsible for a wide range of disorders. FOP is caused by mutations in ALK2.
    • FOP affects less than 200 Americans and less than 1,000 people worldwide.
    • Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.
    | Aug. 18, 2015, 8:57 AM
  • Aug. 11, 2015, 9:01 AM
    • The FDA accepts the Investigational New Drug Application (IND) from La Jolla Pharmaceutical (NASDAQ:LJPC) for LJPC-401, its novel formulation of hepcidin under development for the treatment of iron overload. Preliminary results from a Phase 1 trial are expected by the end of the year.
    • Hepcidin is a naturally occurring regulator of iron adsorption and distribution. Excess iron is a characteristic of certain diseases such as hereditary hemochromatosis (genetic deficiency of hepcidin) and beta thalassemia. If untreated, excess iron can damage organs and eventually lead to death.
    | Aug. 11, 2015, 9:01 AM | 1 Comment
  • Aug. 7, 2015, 8:09 AM
    • La Jolla Pharmaceutical (NASDAQ:LJPC): Q2 EPS of -$0.70 misses by $0.09.
    | Aug. 7, 2015, 8:09 AM
  • Aug. 5, 2015, 10:48 AM
    • LaJolla Pharmaceuticals (LJPC +2.2%) signs two new exclusive license agreements covering its next-generation gentamicin derivatives, LJPC-30Sa and LJPC-30Sb, as antimicrobial agents and for the potential treatment of rare genetic disorders such as cystic fibrosis (CF) and Duchenne muscular dystrophy, enabling the company to pursue its dual development strategy. The agreements are with the Indiana University Research and Technology Corporation and the University of Alabama at Birmingham.
    • Gentamicin is one of the most commonly prescribed hospital antibiotics but it stresses the kidneys. La Jolla's derivatives retain the biologic activity of gentamicin without the kidney-related toxicity.
    • The company believes that gentamicin's effect on gene transcription, intrinsic to its mechanism of action, may have a therapeutic effect in certain human genetic disorders. Previous short-term proof-of-concept studies have shown favorable results in CF but development of gentamicin for long-term treatment has not progressed due to its toxicity profile.
    • La Jolla intends to file an IND with the FDA in the near future which, if approved, will enable it to commence a Phase 1 study.
    | Aug. 5, 2015, 10:48 AM
Company Description
La Jolla Pharmaceutical Co. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics intended to significantly improve outcomes in patients with life-threatening diseases. It focuses on three product candidates: GCS-100, LJPC-501 and... More
Sector: Healthcare
Industry: Drug Related Products
Country: United States